Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Colorectal Neoplasms 28Neoplasms 13Colonic Neoplasms 12Breast Neoplasms 12Prostatic Neoplasms 9Polycythemia Vera 9Venous Thromboembolism 8Multiple Myeloma 8Recurrence 6Carcinoma, Non-Small-Cell Lung 6Rectal Neoplasms 5Thrombocythemia, Essential 4Ovarian Neoplasms 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Esophageal Neoplasms 4Cardiovascular Diseases 4Barrett Esophagus 4Stomach Neoplasms 3Precancerous Conditions 3Melanoma 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Adenomatous Polyps 3Adenoma 3Tobacco Use Disorder 2Thrombosis 2Thromboembolism 2Smoking Cessation 2

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Aspirin × Clear all
NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Peter MacCallum Cancer Centre, Australia

Phase 2 Completed
150 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated
63 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01042704 2017-07-31

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

University of Pittsburgh

Phase 1 Completed
29 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
5 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡